Glycopyrronium: 8 agencies, 2013–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 13.4 years separate the first record, 14 Jan 2013 at SMC (Scotland), from the most recent, 15 Jun 2026 at AWMSG (Wales).
AWMSG (Wales) changed its position: recommended on 22 May 2013, not recommended by 24 Sep 2014.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 8 of 22 records date from 2023 or later.
7 distinct indication wordings are recorded for glycopyrronium by the agencies that label one in English (AWMSG, PBAC and SMC).
2 of these 22 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess glycopyrronium, on 14 Jan 2013; AOTMIT (Poland) did not open a file until 13 Oct 2023 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 11 years in total.
6 of the 8 agencies here assessed glycopyrronium more than once, HAS (France) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for glycopyrronium.
The full ledger for glycopyrronium reads 12 recommended, 3 other, 2 restricted and 2 not assessed, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 20 May 2026 | Sialanar reimbursement recommendation | recommended conditionally | source |
| HAS (France) | 10 Sep 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PBAC (Australia) | 2025 | Primary axillary hyperhidrosis | Recommended | source |
| G-BA (Germany) | 19 Jan 2023 | Axhidrox — benefit assessment §35a | added benefit: not proven | source |
| AWMSG (Wales) | 26 Apr 2019 | The symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years… | outside AWMSG criteria | source |
17 further decisions for glycopyrronium, across 7 agencies, are not shown here. They include the most recent record on file, 15 Jun 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- tiotropium — same ATC class R03B — Obstructive airway diseases
- umeclidinium — same ATC class R03B — Obstructive airway diseases
- sotorasib — also decided by AWMSG in 2026Q2
- teplizumab — also decided by AWMSG in 2026Q2
- osimertinib — also decided by AWMSG in 2026Q2
- lisocabtagene maraleucel — also decided by AWMSG in 2026Q2
Coverage: 22 decisions for glycopyrronium from 8 agencies, 2013 to 2026. Data to 7 Sep 2026. ATC class R03B — Obstructive airway diseases. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.